# Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

> **NCT01562444** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 206 (actual)

## Conditions studied

- Tick Borne Encephalitis
- Virus Diseases

## Interventions

- **OTHER:** Blood draw

## Key facts

- **NCT ID:** NCT01562444
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-08
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-09-30
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2021-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562444, "Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT01562444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*